

【original articles】

1. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, and Suzuki Y. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. *Mod Rheumatol*. 2022; 32(1):41-49.
2. Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, and Suzuki Y. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: A multi-center retrospective cohort study. *Mod Rheumatol*. 2022; 32(1):50-58.
3. Kuramoto N, Saito S, Fujii T, Kaneko Y, Saito R, Tanaka M, Takada H, Nakano K, Saito K, Sugimoto N, Sasaki S, Harigai M, and Suzuki Y. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case control study. *Mod Rheumatol*. 2022; 32(1):24-31.
4. Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, Sugimoto N, Sasaki S, Saito S, Saito R, Kuramoto N, Harigai M, and Suzuki Y. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study. *Mod Rheumatol*. 2022; 32(1):32-40.
5. Tabata K, Kaminaka C, Yasutake M, Matsumiya R, Inaba Y, Yamamoto Y, Jinnin M and Fujii T. Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage. *Intractable Rare Dis Res*. 2022 ; 11(1):1-6.
6. Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, Okamoto N, Takahashi N, Nakajima A, Nakajima A, Tsujimoto N, Nishikawa A, Ishii T, Takeuchi T, and Kuwana M. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. *Mod Rheumatol*. 2022. 33(4):647-656. DOI :10.1093/mr/roac089. PMID: 35932218.
7. Shen M, Wang D, Sennari Y, Zeng Z, Baba R, Morimoto H, Kitamura N, Nakanishi T, Tsukada J, Ueno M, Todoroki Y, Iwata S, Yonezawa, Tanaka Y, Osada Y, Yoshida Y. Pentacyclic triterpenoid ursolic acid induces apoptosis with mitochondrial dysfunction in adult T-cell leukemia cells to promote surrounding cell growth. *Med Oncol*. 39(8):118. 2022
8. Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Iwata S, Kubo S, Sonomoto K, Anan J, Ohkubo N, Inoue Y, Tanaka Y. Impact of serum interleukin 22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: A retrospective study. *Arthritis Res Ther*. 24(1):86. 2022
9. Ueno M, Miyagawa I, Aritomi T, Kimura K, Iwata S, Hanami K, Fukuyo S, Kubo S, Miyazaki Y, Nakayamada S, and Tanaka Y. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. *Arthritis Res Ther*. 24(1):159. 2022
10. Nguyen AP, Yamagata K, Iwata S, Trimova G, Zhang T, Shan Y, Nguyen MP, Sonomoto K, Nakayamada S, Kato S, Tanaka Y. Enhancer RNA commits osteogenesis via microRNA-3129 expression in human bone marrow-derived mesenchymal stem cells. *Inflamm Regen*. 42(1):43. 2022

11. Yamagata K, Nakayamada S, Zhang T, Nguyen AP, Ohkubo N, Iwata S, Kato S, Tanaka Y. IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4<sup>+</sup> T cells in rheumatoid arthritis. *Inflamm Regen*. 2022;42(1):46. 2022
12. Zhang T, Yamagata K, Iwata S, Sonomoto K, Trimova G, Nguyen AP, Hao H, Shan Y, Nguyen MP, Nakayamada S, Tanaka Y. Epstein-Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. *PLoS One*. 17(12):e0279584. 2022

#### 【review】

1. Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. *Front Med (Lausanne)*. 25;9:849120. 2022.

#### 【case report】

1. Fujita Y, Iwata S, Nakano K, Nakayamada S, Miyazaki Y, Kawabe A, Korekoda-Yoshinari H, Nawata A, Tanaka Y. A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. *Modern Rheumatology Case Reports*. 6(2):178-182. 2022
2. Kanda R, Nakano K, Nawata A, Iwata S, Nakayamada S, Tanaka Y. Remission of Granulomatosis with Polyangiitis Only After Resection of Pulmonary Nodule; A case report. *Intern Med*. 61(18):2803-2808. 2022
3. Ikeda N, Yamada S, Yamamoto M, Tanaka K, Fujii T, Tsuji T, Kimoto S, Takahashi S. Two cases of steroid dementia showing partial recovery during 2-year follow-up. *Case Reports PCN Rep*. 2022 Oct 6;1(4):e49. doi: 10.1002/pcn5.49. eCollection 2022 Dec.

#### 【雑誌】

1. 藤井 隆夫. 解説. 免疫介在性炎症性疾患のJAK阻害薬治療において考慮すべき事項. リウマチ科 2022;67(3):360-366.
2. 松宮 遼、藤井 隆夫. 特集 混合性結合組織病(MCTD)診療のupdate. MCTDの三叉神経障害と無菌性髄膜炎. リウマチ科 2022;67(6):679-685.
3. 藤井 隆夫. IV. 関節リウマチの治療 治療各論 生物学的抗リウマチ薬の使い方と安全性. 最新関節リウマチ学(第2版)-寛解・治癒を目指した研究と最新治療- 2022:80(4)369-376
4. 藤井 隆夫. 特集 RA発症前の病態解析の進歩: 自己抗体からの解析. 臨床リウマチ 2022:34:51-59.
5. 岩田 慈, 田中良哉. 最新関節リウマチ学(第2版). IV. 関節リウマチの治療. 治療各論; ウパダシチニブ(Upadacitinib). 日本臨床(増刊号). 80:472-478, 2022.
6. 岩田 慈, 田中良哉. 自己免疫疾患における免疫代謝機構を介したリンパ球の分化・機能. 臨床免疫・アレルギー科. 78(1):1-9, 2022.

#### 【書籍】

1. 藤井 隆夫 14膠原病および類縁疾患「混合性結合組織病」福井次矢、高木 誠、小室一成 編 今日の治療指針2022年度版889-890 医学書院 東京
2. 藤井 隆夫 IV薬物療法の最新指針「02. 関節リウマチにおけるTreat to Target」 関節リウマチ治療実践バイブル(改訂第2版) 148-151 2022 南江堂 東京